Table 2

Base case clinical results: fractures avoided per 1,000 patients
Cohort Evaluated Hip Fractures Vertebral Fractures Wrist Fractures
PMO Patients (100% Female), age 69 years, T-Score = −3.0
historical vertebral + incident vertebral fracture
 Teriparatide vs. No Treatment 95 221 32
 Teriparatide vs. bisphosphonate 66 166 27
incident vertebral fracture
 Teriparatide vs. No Treatment 73 145 27
 Teriparatide vs. bisphosphonate 51 108 22
GIOP Patients (80% Female), age 69 years, T-Score = −2.5
historical vertebral + incident vertebral fracture
 Teriparatide vs. No Treatment 93 304 36
 Teriparatide vs. bisphosphonate 63 227 30
incident vertebral fracture
 Teriparatide vs. No Treatment 85 248 34
 Teriparatide vs. bisphosphonate 57 184 28

Murphy et al.

Murphy et al. BMC Musculoskeletal Disorders 2012 13:213   doi:10.1186/1471-2474-13-213

Open Data